Philips Medical forms research collaboration with CellPoint

Philips Medical Systems will jointly develop better molecular imaging technologies for oncology with Englewood, Colo.-based biotechnology company CellPoint.

The companies will collaborate and share clinical trail costs in order to optimize CellPoint's health imaging agent on Philips' SkyLight gantry-free gamma camera.

The effort to develop a cost-effective, readily accessible molecular imaging technology brings together Philips' SkyLight gamma camera with CellPoint's ethylenedicysteine drug conjugate technology (EC technology). The EC technology would target the tumors, while Philips' nuclear medicine camera to image them.

SkyLight's architecture allows gamma detectors to be mounted into a room's structure or ceiling. The latest version -- SkyLight 2.0 -- allows clinicians to acquire optimal images for molecular agents and drugs/radiopharmaceuticals simultaneously.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.